Phelps Christina M, Tissot Cecile, Buckvold Shannon, Gralla Jane, Ivy D Dunbar, Pietra Biagio A, Miyamoto Shelley D
Children's Hospital of Denver, Aurora, CO, USA.
Pediatr Cardiol. 2011 Jan;32(1):1-7. doi: 10.1007/s00246-010-9795-5. Epub 2010 Oct 21.
We sought to analyze the outcome of hemodynamically significant acute graft rejection in pediatric heart transplant recipients from a single-center experience. Acute graft rejection remains a major cause of morbidity and mortality for patients who undergo orthotopic heart transplantation and has been associated with the severity of the rejection episode. A retrospective review of all children experiencing a hemodynamically significant rejection episode after orthotopic heart transplantation was performed. Fifty-three patients with 54 grafts had 70 rejection episodes requiring intravenous inotropic support. Forty-one percent of these patients required high-dose inotropic support, with the remaining 59% of patients requiring less inotropic support. Overall graft survival to hospital discharge was 41% for patients in the high-dose group compared to 94% in the low-dose group. Six-month graft survival in patients who required high-dose inotropes remained at 41% compared to 44% in the low-dose group. Hemodynamically significant acute graft rejection in pediatric heart transplant recipients is a devastating problem with poor short- and long-term outcomes. Survival to hospital discharge is dismal in patients who require high-dose inotropic support. In contrast, survival to discharge is quite good in patients who require only low-dose inotropic support; however, six-month graft survival in this group is low secondary to a high incidence of graft failure related to worsening or aggressive transplant coronary artery disease.
我们试图通过单中心经验分析小儿心脏移植受者血流动力学显著的急性移植物排斥反应的结果。急性移植物排斥反应仍然是原位心脏移植患者发病和死亡的主要原因,并且与排斥反应发作的严重程度相关。我们对所有原位心脏移植后经历血流动力学显著排斥反应发作的儿童进行了回顾性研究。53例患者的54个移植物发生了70次排斥反应发作,需要静脉注射正性肌力药物支持。这些患者中有41% 需要高剂量正性肌力药物支持,其余59% 的患者需要较少的正性肌力药物支持。高剂量组患者至出院时的移植物总体生存率为41%,而低剂量组为94%。需要高剂量正性肌力药物的患者6个月移植物生存率仍为41%,而低剂量组为44%。小儿心脏移植受者血流动力学显著的急性移植物排斥反应是一个严重的问题,短期和长期预后均较差。需要高剂量正性肌力药物支持的患者出院生存率很低。相比之下,仅需要低剂量正性肌力药物支持的患者出院生存率相当高;然而,由于与移植冠状动脉疾病恶化或进展相关的移植物失败发生率较高,该组患者的6个月移植物生存率较低。